Trials / Completed
CompletedNCT06148181
A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
A Randomized, Double-blind, Placebo-controlled, Phase 1a Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses of ABBV-141 in Healthy Adult Western and Asian Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-141 | Infusion; intravenous (IV) |
| DRUG | Placebo for ABBV-141 | Infusion; IV |
| DRUG | ABBV-141 | Injection; subcutaneous (SC) |
| DRUG | Placebo for ABBV-141 | Injection; SC |
Timeline
- Start date
- 2024-01-29
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2023-11-28
- Last updated
- 2025-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06148181. Inclusion in this directory is not an endorsement.